BioSpace News Archive

Medical Marijuana, Inc. is scheduled to hold its Annual Meeting of Shareholders on Friday, November 30, 2018 at 10:00 a.m. PT on the Internet through a virtual webcast.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that it will redeem $200 million aggregate principal amount of its outstanding 5.625% Senior Notes due 2021, CUSIP Nos. 91911KAD4, C94143AD3 (the “Notes”) on Dec. 31, 2018.

Groundbreaking Research by Oncolytic Virus Pioneer Dr. John Bell will be Presented at the American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting

Dedicated women’s health care professional brings a decade of experience in gynecology and obstetrics care

The Honourable Ginette Petitpas Taylor, Federal Minister of Health, will be joined by the Honourable Filomena Tassi, Minister of Seniors and Member of Parliament for Hamilton West–Ancaster–Dundas, to mark the 16 Days of Activism Against Gender-Based Violence, by announcing funding for projects that will aim to prevent gender-based violence.

The celebration recognizes individuals who have made exceptional contributions to improving the lives of people affected by myeloproliferative neoplasms

In the wake of the rising influence of public and private payers, pharmaceutical companies are seeking more effective ways to work with payer organizations.

Healthcare Trust of America, Inc. (NYSE:HTA), the largest public owner and operator of medical office buildings in the United States is proud to be an Emerald sponsor of St. Joseph Health/ Mission Hospital’s Holiday Gala and will be in attendance during the December 1, 2018 event at the Monarch Beach Resort in Orange County.

Amgen and UCB today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients